Evaluation of inhaled medications to improve breathing during exercise in patients with Pulmonary Arterial Hypertensio
Not Applicable
- Conditions
- pulmonary arterial hypertensionC08.381.423
- Registration Number
- RBR-66359j
- Lead Sponsor
- niversidade Federal do Rio Grande do Sul
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients diagnosed with pulmonary arterial hypertension according to the Nice classification, 2013, confirmed by right cardiac catheterization at rest. Stable drug treatment in the last 3 months. Symptomatic, with dyspnoea. In functional class of the New York Heart Association II and III.
Exclusion Criteria
Non-HAP Pulmonary Hypertension, that is, Groups 2 to 5 will be excluded, as well as patients with other comorbidities that may cause limitation of exercise capacity. Use of prolonged home oxygen therapy. That they present FEV1VF <0.7. Be involved in regular physical activity programs in the last 3 to 6 months.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dyspnea assessed by the Borg categorical scale during isotype (highest common time in all tests) in high intensity constant load ECT (cardiopulmonary exercise test) comparing inhaled bronchodilator, furosemide and placebo.
- Secondary Outcome Measures
Name Time Method